Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 989 GBX 0.05% Market Closed
Market Cap: 4.4B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Relative Value

The Relative Value of one HIK stock under the Base Case scenario is 4 851.92 GBX. Compared to the current market price of 1 989 GBX, Hikma Pharmaceuticals PLC is Undervalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HIK Relative Value
Base Case
4 851.92 GBX
Undervaluation 59%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
88
vs Industry
55
Median 3Y
1.9
Median 5Y
2.2
Industry
2.5
Forward
0
vs History
36
vs Industry
16
Median 3Y
19.7
Median 5Y
16.3
Industry
21.8
Forward
0.1
vs History
71
vs Industry
38
Median 3Y
8.9
Median 5Y
9.6
Industry
16.1
vs History
58
vs Industry
20
Median 3Y
20.7
Median 5Y
20.7
Industry
23.8
vs History
77
vs Industry
33
Median 3Y
2.4
Median 5Y
2.5
Industry
2.1
vs History
46
vs Industry
7
Median 3Y
31.3
Median 5Y
26
Industry
2.7
Forward
0.3
vs History
36
vs Industry
3
Median 3Y
65.5
Median 5Y
50.3
Industry
5.2
vs History
17
vs Industry
3
Median 3Y
102.3
Median 5Y
96.1
Industry
13.5
Forward
1.1
vs History
36
vs Industry
2
Median 3Y
151.7
Median 5Y
115.8
Industry
16.8
Forward
1.3
vs History
36
vs Industry
3
Median 3Y
160.3
Median 5Y
148.2
Industry
15.2
vs History
55
vs Industry
2
Median 3Y
259.3
Median 5Y
247
Industry
19.3
vs History
46
vs Industry
5
Median 3Y
23.2
Median 5Y
17.4
Industry
1.9

Multiples Across Competitors

HIK Competitors Multiples
Hikma Pharmaceuticals PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Hikma Pharmaceuticals PLC
LSE:HIK
4.4B GBP 1.8 19.4 111.9 151.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
754.7B USD 18.5 90.3 48.4 54
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 4 23.9 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
251.8B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.5 254
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average P/S: 382 942.1
1.8
18%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average P/E: 31
19.4
200%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average EV/EBITDA: 424.8
111.9
7%
15
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.4
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.5
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Hikma Pharmaceuticals PLC
LSE:HIK
Average EV/EBIT: 1 825.3
151.6
31%
5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
254
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top